Levels of mortgage approvals have been remarkably resilient in the first part of this year which seems surprising given the concerns about the health of the UK economy as we enter into Q2, and some ...

Jeanne Whalen writes about the U.S. economy from the Chicago bureau. She previously covered healthcare, general news and ...

Elon Musk’s X Holdings Corp. is evolving from a social media platform powered by mainstream advertisers to one betting on ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Thus far in the calendar year 2025, the stock price of GSK Pharma has zoomed 40 per cent, as against 1.8 per cent rise in BSE ...

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Swiss pharmaceuticals powerhouse Roche says it plans to invest $50 billion in the United States over the next five years and ...

Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see. Please watch the video at Investors.com - Do Your Stocks Meet This Key ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...